Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Mathis, Sarah E ^a,b   Alberico, Anthony ^a   Nande, Rounak ^a,b   Neto, Walter ^a,b   Lawrence, Logan ^a,b   McCallister, Danielle R ^a,b   Denvir, James ^a,b   Kimmey, Gerrit A ^c   Mogul, Mark ^a   Oakley III, Gerard ^a   Denning, Krista L ^a   Dougherty, Thomas ^a   Valluri, Jagan V ^b   Claudio, Pier Paolo ^a,b  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MARSHALL UNIVERSITY   (United States)

^c St Mary's Medical Center Huntington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL ISOTHIOCYANATE; BEVACIZUMAB; BUSULFAN; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IRINOTECAN; LOMUSTINE; METHOTREXATE; OXALIPLATIN; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM LIKE CELL; CASE REPORT; CHEMOTHERAPY SENSITIVITY ASSAY; COLD TOLERANCE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TOLERABILITY; EPENDYMOMA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFANT; LAMINECTOMY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTON THERAPY; RADIOSURGERY; SIDE EFFECT; STEM CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; YOUNG ADULT; ANIMAL; BRAIN NEOPLASMS; CANCER STEM CELL; DRUG DELIVERY SYSTEM; METABOLISM; NUDE MOUSE; PATHOLOGY;

ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; EPENDYMOMA; FEMALE; HUMANS; INFANT; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940247516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105710     Document Type: Article

References (49)

1. Hanbali F, Fourney DR, Marmor E, Suki D, Rhines LD, et al. (2002) Spinal cord ependymoma: radical surgical resection and outcome. Neurosurgery 51: 1162-1172; discussion 1172-1164.
2. Duncan J, Hoffman H (1995) Intracranial ependymomas. In: Kaye A, Lows E, Jr. editors. Brain Tumors. Edinburgh: Churchill Livingstone. pp. 493-504.
3. Cooper IS, Craig WM, Kernohan JW (1951) Tumors of the spinal cord; primary extramedullary gliomas. Surg Gynecol Obstet 92: 183-190.
4. Bouffet E, Foreman N (1999) Chemotherapy for intracranial ependymomas. Child's nervous system: ChNS: official journal of the International Society for Pediatric Neurosurgery 15: 563-570.
5. Chou PM, Barquin N, Gonzalez-Crussi F, Ridaura Sanz C, Tomita T, et al. (1996) Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biologic study. Pediatric pathology & laboratory medicine: journal of the Society for Pediatric Pathology, affiliated with the International Paediatric Pathology Association 16: 551-561.
6. O'Brien CA, Kreso A, Jamieson CH (2010) Cancer stem cells and self-renewal. Clin Cancer Res 16: 3113-3120.
7. Aimola P, Desiderio V, Graziano A, Claudio PP (2010) Stem cells in cancer therapy: From their role in pathogenesis to their use as therapeutic agents. Drug News Perspect 23: 175-183.
8. Kelly SE, Di Benedetto A, Greco A, Howard CM, Sollars VE, et al. (2010) Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications. PLoS One 5: e10035.
9. Malik B, Nie D (2012) Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed) 4: 2142-2149.
10. Yu Y, Ramena G, Elble RC (2012) The role of cancer stem cells in relapse of solid tumors. Front Biosci (Elite Ed) 4: 1528-1541.
11. Modena P, Buttarelli FR, Miceli R, Piccinin E, Baldi C, et al. (2012) Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro-oncology 14: 1346-1356.
12. van Meerloo J, Kaspers GJ, Cloos J (2011) Cell sensitivity assays: the MTT assay. Methods Mol Biol 731: 237-245.
13. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 22: 659-661.
14. Di Pasqua AJ, Hong C, Wu MY, McCracken E, Wang X, et al. (2010) Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocyanates. Chem Res Toxicol 23: 1307-1309.
15. Wu X, Zhou QH, Xu K (2009) Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin 30: 501-512.
16. Merchant TE (2002) Current management of childhood ependymoma. Oncology 16: 629-642, 644; discussion 645-626, 648.
17. Chamberlain MC, Tredway TL (2011) Adult primary intradural spinal cord tumors: a review. Curr Neurol Neurosci Rep 11: 320-328.
18. Duffau H, Gazzaz M, Kujas M, Fohanno D (2000) Primary intradural extramedullary ependymoma: case report and review of the literature. Spine (Phila Pa 1976) 25: 1993-1995.
19. McCormick PC, Post KD, Stein BM (1990) Intradural extramedullary tumors in adults. Neurosurg Clin N Am 1: 591-608.
20. Pejavar S, Polley MY, Rosenberg-Wohl S, Chennupati S, Prados MD, et al. (2012) Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol 106: 367-375.
21. Song KW, Shin SI, Lee JY, Kim GL, Hyun YS, et al. (2009) Surgical results of intradural extramedullary tumors. Clin Orthop Surg 1: 74-80.
22. Vandertop WP (2003) Spinal cord ependymoma: radical surgical resection and outcome. Neurosurgery 53: 246; author reply 246-247.
23. Kocak Z, Garipagaoglu M, Adli M, Uzal MC, Kurtman C (2004) Spinal cord ependymomas in adults: analysis of 15 cases. J Exp Clin Cancer Res 23: 201-206. (Pubitemid 38943550)
24. Lin YH, Huang CI, Wong TT, Chen MH, Shiau CY, et al. (2005) Treatment of spinal cord ependymomas by surgery with or without postoperative radiotherapy. J Neurooncol 71: 205-210.
25. Metellus P, Figarella-Branger D, Guyotat J, Barrie M, Giorgi R, et al. (2008) Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer 113: 175-185. (Pubitemid 351976399)
26. Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, et al. (2004) A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 100: 1221-1229. (Pubitemid 38325951)
27. Reni M, Gatta G, Mazza E, Vecht C (2007) Ependymoma. Crit Rev Oncol Hematol 63: 81-89. (Pubitemid 46810282)
28. Iunes EA, Stavale JN, de Cassia Caldas Pessoa R, Ansai R, Onishi FJ, et al. (2011) Multifocal intradural extramedullary ependymoma. Case report. J Neurosurg Spine 14: 65-70.
29. Breidenbach M, Rein DT, Mallmann P, Kurbacher CM (2002) Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anticancer Drugs 13: 173-176. (Pubitemid 34183648)
30. Brower SL, Fensterer JE, Bush JE (2008) The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol 414: 57-78.
31. Kleinhans R, Brischwein M, Wang P, Becker B, Demmel F, et al. (2012) Sensorbased cell and tissue screening for personalized cancer chemotherapy. Med Biol Eng Comput 10.1007/s11517-011-0855-7.
32. Michalova E, Poprach A, Nemeckova I, Nenutil R, Valik D, et al. (2008) [Chemosensitivity prediction in tumor cells ex vivo-difficulties and limitations of the method]. Klin Onkol 21: 93-97.
33. Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, et al. (1997) The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 8: 756-762. (Pubitemid 27451817)
34. Tsubouchi H, Takao S, Aikou T (2000) Sensitivity of human pancreatic adenocarcinoma tumor lines to chemotherapy, radiotherapy, and hyperthermia. Hum Cell 13: 203-212.
35. Wichmann G, Horn IS, Boehm A, Mozet C, Tschop K, et al. (2009) Single tissue samples from head and neck squamous cell carcinomas are representative regarding the entire tumor's chemosensitivity to cisplatin and docetaxel. Onkologie 32: 264-272.
36. Ballard KS, Tedjarati SS, Robinson WR, Homesley HD, Thurston EL (2010) Embryonal rhabdomyosarcoma: adjuvant and ex vivo assay-directed chemotherapy. Int J Gynecol Cancer 20: 561-563.
37. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, et al. (2006) Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16: 194-201.
38. Herzog TJ, Krivak TC, Fader AN, Coleman RL (2010) Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 203: 68 e61-66.
39. Huh WK, Cibull M, Gallion HH, Gan CM, Richard S, et al. (2011) Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma. Int J Gynecol Cancer 21: 494-499.
40. Ness RB, Wisniewski SR, Eng H, Christopherson W (2002) Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer Res 22: 1145-1149. (Pubitemid 34836164)
41. Ochs RL, Burholt D, Kornblith P (2005) The ChemoFx assay: an ex vivo cell culture assay for predicting anticancer drug responses. Methods Mol Med 110: 155-172.
42. Peters D, Freund J, Ochs RL (2005) Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 4: 1605-1616. (Pubitemid 41556444)
43. Rice SD, Cassino TR, Sakhamuri L, Song N, Williams KE, et al. (2011) An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab. Cancer Biol Ther 11: 196-203.
44. Rice SD, Heinzman JM, Brower SL, Ervin PR, Song N, et al. (2010) Analysis of chemotherapeutic response heterogeneity and drug clustering based on mechanism of action using an in vitro assay. Anticancer Res 30: 2805-2811.
45. Suchy SL, Hancher LM, Wang D, Ervin PR, Jr., Brower SL (2011) Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer. Cancer Biol Ther 11: 1059-1064.
46. Mi L, Hood BL, Stewart NA, Xiao Z, Govind S, et al. (2011) Identification of potential protein targets of isothiocyanates by proteomics. Chem Res Toxicol 24: 1735-1743.
47. Zhang Y (2001) Molecular mechanism of rapid cellular accumulation of anticarcinogenic isothiocyanates. Carcinogenesis 22: 425-431.
48. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, et al. (1999) Progress in cancer chemoprevention. Ann N Y Acad Sci 889: 1-13. (Pubitemid 30040420)
49. Lamy E, Scholtes C, Herz C, Mersch-Sundermann V (2011) Pharmacokinetics and pharmacodynamics of isothiocyanates. Drug Metab Rev 43: 387-407.